Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
AgomAb Therapeutics N.V.
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
June 23, 2026
Agomab Announces Results of Annual General Meeting
May 27, 2026
Agomab to Participate in Upcoming Conferences
May 14, 2026
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
April 23, 2026
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026
Agomab Announces Closing of Initial Public Offering
February 10, 2026
Agomab Announces Pricing of Initial Public Offering
February 6, 2026
Agomab Announces Launch of Initial Public Offering
February 2, 2026